Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch
of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution).
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z2 Ophthalmic Solution USP, 0.004% of Sandoz, Inc.
According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Z Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
